Patents by Inventor Janet Dawson King

Janet Dawson King has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Publication number: 20170327553
    Abstract: The present invention provides peptide tags that can be linked to a therapeutic molecule in order to decrease the clearance of the therapeutic molecule from the synovial joint, thereby increasing its intra-articular half-life.
    Type: Application
    Filed: June 24, 2015
    Publication date: November 16, 2017
    Applicant: Novartis AG
    Inventors: Janet DAWSON KING, Joy GHOSH, Barbara NUESSLEIN-HILDESHEIM
  • Patent number: 8258128
    Abstract: The present invention relates to novel aza-thia-benzoazulene derivatives of formula I as defined in the claims, their preparation, the use of these novel compounds for the preparation of pharmaceutical compositions, the use of these novel compounds and compositions for managing arthritis and arthritis-related conditions as well as in the treatment of pain in animals and humans. More particularly, the present invention relates to pharmaceutical, preferably veterinary compositions and methods for reducing inflammation and pain associated with acute inflammation of body parts, particularly joints, due to injury or due to arthritic conditions or other disease conditions.
    Type: Grant
    Filed: February 21, 2007
    Date of Patent: September 4, 2012
    Assignee: Novartis AG
    Inventors: Pietro Bollinger, Mahavir Prashad, Bernhard Riss, Janet Dawson King, Peter C. Hiestand, Yugang Liu, Jonathan King, Vincent Schmid, Friedrich Schuerch
  • Publication number: 20100144835
    Abstract: The present invention relates to the use of a GPR4 inhibitor for the manufacture of a medicament for the inhibition of angiogenesis, for instance for the inhibition of tumour growth in the treatment of cancer. In a preferred embodiment, said inhibitor is a siRNA, preferably double-stranded. In addition, the present invention further encompasses non-human animals wherein the GPR4 has been inactivated, for instance a knock-out mouse lacking GPR4, and the use of said animals as an experimental model for angiogenesis and for screening for compounds modulating angiogenesis.
    Type: Application
    Filed: December 13, 2007
    Publication date: June 10, 2010
    Inventors: Klaus Seuwen, Eric Billy, Thomas Suply, Lorenza Wyder, Janet Dawson King, Marie-Gabrielle Ludwig, Matthias Mueller, Puneeta Nath, Carol Elizabeth Jones
  • Publication number: 20090131408
    Abstract: The present invention relates to novel aza-thia-benzoazulene derivatives of formula I as defined in the claims, their preparation, the use of these novel compounds for the preparation of pharmaceutical compositions, the use of these novel compounds and compositions for managing arthritis and arthritis-related conditions as well as in the treatment of pain in animals and humans. More particularly, the present invention relates to pharmaceutical, preferably veterinary compositions and methods for reducing inflammation and pain associated with acute inflammation of body parts, particularly joints, due to injury or due to arthritic conditions or other disease conditions.
    Type: Application
    Filed: February 21, 2007
    Publication date: May 21, 2009
    Inventors: Pietro Bollinger, Mahavir Prashad, Bernhard Riss, Janet Dawson King, Peter C. Hiestand, Yugang Liu, Jonathan King, Vincent Schmid, Friedrich Schuerch
  • Patent number: 6911440
    Abstract: The invention relates to the treatment of an inflammatory disease, especially an inflammatory rheumatoid or rheumatic disease, and/or pain with an inhibitor of the activity of VEGF receptor tyrosine kinase of the formula I, the substituents being defined in the specification; as well as to new phthalazine derivatives; processes for the preparation thereof, the application thereof in a process for the treatment of the human or animal body; the use thereof for the treatment of a disease, especially a disease caused by ocular neovascularization, such as age-related macula degeneration or diabetic retinopathy, or other diseases that respond to the inhibition of tyrosine kinases, such as a proliferative disease; a method for the treatment of such disease in mammals; and the use of such a compound for the manufacture of a pharmaceutical preparation for the treatment especially of a disease as mentioned above.
    Type: Grant
    Filed: November 26, 2003
    Date of Patent: June 28, 2005
    Assignee: Novartis AG
    Inventors: Guido Bold, Janet Dawson King, Jörg Frei, Richard Heng, Paul William Manley, Bernhard Wietfeld, Jeanette Marjorie Wood
  • Publication number: 20040142934
    Abstract: The invention relates to the treatment of an inflammatory disease, especially an inflammatory rheumatoid or rheumatic disease, and/or pain with an inhibitor of the activity of VEGF receptor tyrosine kinase of the formula I, 1
    Type: Application
    Filed: November 26, 2003
    Publication date: July 22, 2004
    Inventors: Guido Bold, Janet Dawson King, Jorg Frei, Richard Heng, Paul William Manley, Bernhard Wietfeld, Jeanette Marjorie Wood
  • Patent number: 6686347
    Abstract: The invention relates to the treatment of an inflammatory disease, especially an inflammatory rheumatoid or rheumatic disease, and/or pain with an inhibitor of the activity of VEGF receptor tyrosine kinase of the formula I, the substituents being defined in the specification; as well as to new phthalazine derivatives; processes for the preparation thereof; the application thereof in a process for the treatment of the human or animal body; the use thereof for the treatment of a disease, especially a disease caused by ocular neovascularization, such as age-related macula degeneration or diabetic retinopathy, or other diseases that respond to the inhibition of tyrosine kinases, such as a proliferative disease; a method for the treatment of such disease in mammals; and the use of such a compound for the manufacture of a pharmaceutical preparation for the treatment especially of a disease as mentioned above.
    Type: Grant
    Filed: September 26, 2001
    Date of Patent: February 3, 2004
    Assignee: Novartis AG
    Inventors: Guido Bold, Janet Dawson King, Jörg Frei, Richard Heng, Paul William Manley, Bernhard Wietfeld, Jeanette Marjorie Wood
  • Publication number: 20030013718
    Abstract: The invention relates to the treatment of an inflammatory disease, especially an inflammatory rheumatoid or rheumatic disease, and/or pain with an inhibitor of the activity of VEGF receptor tyrosine kinase of the formula I, 1
    Type: Application
    Filed: September 26, 2001
    Publication date: January 16, 2003
    Inventors: Guido Bold, Janet Dawson King, Jorg Frei, Richard Heng, Paul William Manley, Bernhard Wietfeld, Jeanette Marjorie Wood